LivaNova PLC (NASDAQ:LIVN – Get Free Report) CFO Alex Shvartsburg sold 2,500 shares of the firm’s stock in a transaction dated Thursday, November 12th. The stock was sold at an average price of $90.91, for a total transaction of $227,275.00. Following the completion of the transaction, the chief financial officer directly owned 42,147 shares in the company, valued at $3,831,583.77. This represents a 5.60% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
LivaNova Stock Performance
LIVN stock traded up $1.12 during midday trading on Friday, reaching $91.32. The company had a trading volume of 742,276 shares, compared to its average volume of 764,040. The firm has a market capitalization of $5.03 billion, a PE ratio of 30.44 and a beta of 0.91. The stock has a 50 day moving average price of $80.32 and a 200 day moving average price of $74.22. LivaNova PLC has a fifty-two week low of $52.37 and a fifty-two week high of $99.38. The company has a quick ratio of 1.22, a current ratio of 1.46 and a debt-to-equity ratio of 0.22.
LivaNova (NASDAQ:LIVN – Get Free Report) last announced its quarterly earnings results on Wednesday, November 4th. The company reported $1.23 earnings per share for the quarter, topping analysts’ consensus estimates of $1.06 by $0.17. The business had revenue of $393.15 million for the quarter, compared to analysts’ expectations of $381.13 million. LivaNova had a return on equity of 16.10% and a net margin of 13.01%. The business’s quarterly revenue was up 9.9% on a year-over-year basis. During the same period in the prior year, the firm earned $1.11 EPS. Analysts anticipate that LivaNova PLC will post 3.76 earnings per share for the current year.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently made changes to their positions in the stock. Dimensional Fund Advisors LP raised its holdings in LivaNova by 2.1% during the first quarter. Dimensional Fund Advisors LP now owns 1,826,248 shares of the company’s stock worth $116,067,000 after purchasing an additional 38,320 shares in the last quarter. Janus Henderson Group PLC boosted its stake in LivaNova by 1,978.8% during the 1st quarter. Janus Henderson Group PLC now owns 471,379 shares of the company’s stock valued at $29,961,000 after purchasing an additional 448,703 shares in the last quarter. Arrowstreet Capital Limited Partnership bought a new position in LivaNova during the 1st quarter valued at $18,327,000. Sei Investments Co. increased its position in shares of LivaNova by 56.6% during the 1st quarter. Sei Investments Co. now owns 218,805 shares of the company’s stock valued at $13,907,000 after purchasing an additional 79,088 shares during the period. Finally, Renaissance Technologies LLC increased its position in shares of LivaNova by 15.7% during the 1st quarter. Renaissance Technologies LLC now owns 183,000 shares of the company’s stock valued at $11,631,000 after purchasing an additional 24,900 shares during the period. 97.64% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets
A number of research firms recently weighed in on LIVN. Robert W. Baird increased their price objective on shares of LivaNova from $95.00 to $111.00 and gave the stock an “outperform” rating in a report on Thursday, November 5th. Wall Street Zen downgraded shares of LivaNova from a “strong-buy” rating to a “buy” rating in a research report on Saturday, November 7th. Raymond James Financial set a $120.00 target price on shares of LivaNova in a research note on Wednesday, November 4th. Piper Sandler reissued an “overweight” rating and set a $90.00 target price (up from $87.00) on shares of LivaNova in a research note on Wednesday, September 2nd. Finally, Jefferies Financial Group restated a “buy” rating on shares of LivaNova in a research report on Wednesday, November 4th. Nine equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, LivaNova has a consensus rating of “Moderate Buy” and a consensus price target of $101.22.
Read Our Latest Stock Report on LIVN
LivaNova Company Profile
LivaNova plc is a global medical technology company that develops and manufactures products for cardiovascular care and neuromodulation. The company was formed in 2015 through the combination of Cyberonics and Sorin Group. In neuromodulation, LivaNova’s VNS Therapy system delivers vagus nerve stimulation and is used as an adjunctive treatment for certain people with drug-resistant epilepsy and treatment-resistant depression. Its cardiovascular products support cardiac surgery and include heart-lung machines, oxygenators and related perfusion equipment.
Featured Articles
- Five stocks we like better than LivaNova
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.
